New Drug Treats Cataracts Without the Need for Surgery
A revolutionary new treatment for cataracts has shown extremely positive results in laboratory tests, giving hope that the condition, that currently can only be cured with surgery, could soon be treated with drugs.
According to the World Health Organization (WHO), 65.2 million people worldwide are living with cataracts, the leading cause of blindness and vision impairment worldwide. Cataract is a clouding of the eye lens that is caused by a disorganisation of the proteins in the lens that leads to clumps of protein forming that scatter light and severely reduce transmission to the retina. This often occurs with age, but can also be caused by the eye’s overexposure to the sun or injury, as well as smoking, medical conditions such as diabetes, and some medications.
Surgery can correct the condition by replacing the lens with an artificial one. A team of international scientists, led by Professor Barbara Pierscionek, Deputy Dean (Research and Innovation) in the Faculty of Health, Education, Medicine and Social Care at Anglia Ruskin University (ARU), have been carrying out advanced optical tests on an oxysterol compound that had been proposed as an anti-cataract drug.
The compound oxysterol, is an oxygenated derivative of cholesterol that plays a role in the regulation and transport of cholesterol. This means that the protein organisation of the lens is being restored, resulting in the lens being better able to focus. This was supported by a reduction in lens opacity in 46% of cases.
The researchers tested an assortment of 35 wild mice and mice genetically altered to develop lens cloudiness through an alteration of their αB-crystallin or αA-crystallin proteins. In the right eye of 26 mice, the researchers administered a single drop of an oxysterol compound, VP1-001Trusted Source, directly onto the ocular surface. Meanwhile, they gave a neutral drop of cyclodextrin in their left eyes. Nine mice were left untreated as a control group. The target of the treatment was the αA- and αB-crystallin mutations that often cause cataracts in aging.
The results have been published today in the peer-reviewed journal Investigative Ophthalmology and Visual Science.
Source: https://aru.ac.uk/
and
https://www.thebrighterside.news/
Recent Comments